Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs
作者： Oraporn Sitburana , Susan Rountree , William G. Ondo
DOI: 10.1016/J.JNS.2008.04.026
关键词:
摘要: Atypical antipsychotics (AA) are generally associated with weight gain. We determined body mass index (BMI) change in Parkinson's disease (PD) before and after taking AA compared against PD controls Alzheimer's (AD) patients on AA. In 66 consecutive subjects started who had accurate weights for more than 6 months initiation of AA, we use, a control group sixty-one sex-matched subjects, twenty-eight AD A linear regression model was created to compare changes. Fifty-nine complete data, quetiapine (n=53) clozapine (n=6). The mean BMI the period starting 0.00 kg/m(2)/month over 1.95+/-1.41 years. After lost 0.03 (95% CI 0.62-1.21, P<0.0001), comparing same 61 controls, loss 0.01 0.15-0.94, P=0.007) vs. controls. 28 increased 0.26-0.83, seen PD/AA group, AD, suggest uniquely altered homeostasis PD.
elsevier.com
bcm.edu 
sci-hub.se 参考文章(34)
J. Vardi, Z. Oberman, I. Rabey, M. Streifler, D. Ayalon, M. Herzberg, Weight loss in patients treated long-term with levodopa Journal of the Neurological Sciences. ,vol. 30, pp. 33- 40 ,(1976) , 10.1016/0022-510X(76)90253-7
A. J. Hughes, S. E. Daniel, S. Blankson, A. J. Lees, A clinicopathologic study of 100 cases of Parkinson's disease. JAMA Neurology. ,vol. 50, pp. 140- 148 ,(1993) , 10.1001/ARCHNEUR.1993.00540020018011
R. Doody, V. Pavlik, Paul Massman, Mary Kenan, Stephanie Yeh, Suzanne Powell, Norma Cooke, Carmel Dyer, Jasenka Demirovic, S. Waring, Wenyaw Chan, Changing Patient Characteristics and Survival Experience in an Alzheimer’s Center Patient Cohort Dementia and Geriatric Cognitive Disorders. ,vol. 20, pp. 198- 208 ,(2005) , 10.1159/000087300
Carlos Juri, Pedro Chan??, John Tapia, Carolina Kunstmann, Teresa Parrao, Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clinical Neuropharmacology. ,vol. 28, pp. 185- 187 ,(2005) , 10.1097/01.WNF.0000174932.82134.E2
Hatice Kumru, Joan Santamaria, Francesc Valldeoriola, Maria J. Marti, Eduardo Tolosa, Increase in body weight after pramipexole treatment in Parkinson's disease. Movement Disorders. ,vol. 21, pp. 1972- 1974 ,(2006) , 10.1002/MDS.21086
K. Shannak, A. Rajput, B. Rozdilsky, S. Kish, J. Gilbert, O. Hornykiewicz, Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Research. ,vol. 639, pp. 33- 41 ,(1994) , 10.1016/0006-8993(94)91761-2
Heiko Braak, Estifanos Ghebremedhin, Udo Rüb, Hansjürgen Bratzke, Kelly Del Tredici, Stages in the development of Parkinson’s disease-related pathology Cell and Tissue Research. ,vol. 318, pp. 121- 134 ,(2004) , 10.1007/S00441-004-0956-9
Jose M. Rabey, Tatiana Prokhorov, Ala Miniovitz, Eugenia Dobronevsky, Colin Klein, Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Movement Disorders. ,vol. 22, pp. 313- 318 ,(2007) , 10.1002/MDS.21116
Joyce G. Small, Quetiapine in Patients With Schizophrenia Archives of General Psychiatry. ,vol. 54, pp. 549- 557 ,(1997) , 10.1001/ARCHPSYC.1997.01830180067009
S. Palhagen, B. Lorefalt, M. Carlsson, W. Ganowiak, G. Toss, M. Unosson, A.-K. Granerus, Does l‐dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease? Acta Neurologica Scandinavica. ,vol. 111, pp. 12- 20 ,(2005) , 10.1111/J.1600-0404.2004.00364.X